BRICANYL TURBUHALER POWDER (METERED DOSE)

Land: Kanada

Tungumál: enska

Heimild: Health Canada

Virkt innihaldsefni:

TERBUTALINE SULFATE

Fáanlegur frá:

ASTRAZENECA CANADA INC

ATC númer:

R03AC03

INN (Alþjóðlegt nafn):

TERBUTALINE

Skammtar:

0.5MG

Lyfjaform:

POWDER (METERED DOSE)

Samsetning:

TERBUTALINE SULFATE 0.5MG

Stjórnsýsluleið:

INHALATION

Einingar í pakka:

200

Gerð lyfseðils:

Prescription

Lækningarsvæði:

SELECTIVE BETA 2-ADRENERGIC AGONISTS

Vörulýsing:

Active ingredient group (AIG) number: 0110482003; AHFS:

Leyfisstaða:

APPROVED

Leyfisdagur:

2000-05-01

Vara einkenni

_ _
BRICANYL
®
TURBUHALER
®
Product Monograph_ _
_Page 1 of 23_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
BRICANYL
®
TURBUHALER
®
terbutaline sulfate
Dry powder, 0.5 mg/dose, Oral Inhalation
Bronchodilator
AstraZeneca Canada Inc.
1004 Middlegate Road
Mississauga, Ontario
L4Y 1M4
www.astrazeneca.ca
Date of Initial Authorization:
NOV 16, 1988
Date of Revision:
MAY 24, 2023
Submission Control Number: 270964
BRICANYL
®
, TURBUHALER
®
and the AstraZeneca logo are registered trademarks of
AstraZeneca AB, used under license by AstraZeneca Canada Inc.
© AstraZeneca Canada Inc. 2023
_ _
BRICANYL
®
TURBUHALER
®
Product Monograph_ _
_Page 2 of 23_
RECENT MAJOR LABEL CHANGES
1 INDICATIONS, 1.1 Pediatrics
06/2021
1 INDICATIONS, 1.2 Geriatrics
06/2021
2 CONTRAINDICATIONS
06/2021
7 WARNINGS AND PRECAUTIONS, General
12/2022
7 WARNINGS AND PRECAUTIONS, Sensitivity/Resistance
06/2021
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.........................................................................................
2
TABLE OF CONTENTS
...............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................................. 4
1
INDICATIONS
...................................................................................................................
4
1.1
Pediatrics
.................................................................................................................
4
1.2
Geriatrics
.................................................................................................................
4
2
CONTRAINDICATIONS
...................................................................................................
4
4
DOSAGE AND ADMINISTRATION
..................................................................................
4
4.1
Dosing Considerations
.................